Cargando…
New drugs, new challenges for dermatologists: mucocutaneous ulcers secondary to everolimus
Everolimus, a mammalian target of rapamycin inhibitor, is an emerging drug, which is being increasingly applied in oncology and solid organ transplantation. Oral ulcers are a frequent side effect associated with this immunosupressor. We report the case of a renal transplant recipient who developed d...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Sociedade Brasileira de Dermatologia
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540539/ https://www.ncbi.nlm.nih.gov/pubmed/26312705 http://dx.doi.org/10.1590/abd1806-4841.20153672 |